Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary

Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.

To assess the effect of long-term treatment by Genotonorm on linear growth

Inclusion Criteria:

• All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014
• All patients who have stopped during one year will be included if a signed written informed consent

Exclusion Criteria:

• Endocrine disease, except well substituted hypothyroidism
• Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)